Chemomab Reports New Peer-Reviewed Publication Reinforcing The Clinical Association Of Its CCL24 Target With Disease Severity and Mortality In Systemic Sclerosis
Chemomab Reports New Peer-Reviewed Publication Reinforcing The Clinical Association Of Its CCL24 Target With Disease Severity and Mortality In Systemic Sclerosis
Chemomab 报告了新的同行评审出版物，强化了其 CCL24 靶点与系统性硬化症疾病严重程度和死亡率的临床关系
Longitudinal Study of a 200+ Real-World Patient Cohort Further Validates CCL24 as a Novel Target for Systemic Sclerosis (SSc), Showing that It is Associated with Disease Severity Across the Fibrotic and Vascular Manifestations of SSc
对 200 多名现实世界患者群体的纵向研究进一步证实 CCL24 是系统性硬化 (ssC) 的新靶标，表明它与 ssC 的纤维化和血管表现形式中的疾病严重程度有关
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。